We are live on ! Find out more
HS

HighVista Strategies Portfolio holdings

AUM $362M
1-Year Est. Return 230.96%
This Fund
S&P 500
This Quarter Est. Return
+12.73%
1 Year Est. Return
+230.96%
3 Year Est. Return
+518.4%
5 Year Est. Return
+644.94%
10 Year Est. Return
+2,223.31%
AUM
$362M
AUM Growth
-$26.1M
Cap. Flow
-$33.3M
Cap. Flow %
-9.19%
Top 10 Hldgs %
27.18%
Holding
180
New
35
Increased
46
Reduced
71
Closed
24

Top Buys

1
ABVX
Abivax
ABVX
+$4.86M
2
NRIX icon
Nurix Therapeutics
NRIX
+$3.76M
3
IVA
Inventiva
IVA
+$3.75M
4
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$3.21M
5
DFTX
Definium Therapeutics
DFTX
+$3.15M

Top Sells

1
VRDN icon
Viridian Therapeutics
VRDN
+$7.08M
2
COGT icon
Cogent Biosciences
COGT
+$5.16M
3
RVMD icon
Revolution Medicines
RVMD
+$5.14M
4
CDTX
Cidara Therapeutics
CDTX
+$5.06M
5
ACLX
Arcellx
ACLX
+$4.89M

Sector Composition

1 Healthcare 66.93%
2 Technology 9.01%
3 Industrials 5.47%
4 Consumer Discretionary 2.89%
5 Financials 2.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
JD icon
151
JD.com
JD
$40B
$398K 0.11%
13,463
-4,000
-23% -$113K
MBX
152
MBX Biosciences
MBX
$2.99B
$342K 0.09%
+11,472
New +$390K
KYMR icon
153
Kymera Therapeutics
KYMR
$9.52B
$315K 0.09%
3,785
-3,050
-45% -$242K
BZ icon
154
Kanzhun
BZ
$6.66B
$285K 0.08%
21,298
+700
+3% +$11.9K
TCOM icon
155
Trip.com Group
TCOM
$26.7B
$273K 0.08%
5,484
-5,162
-48% -$301K
CNTA
156
DELISTED
Centessa Pharmaceuticals
CNTA
$237K 0.07%
5,964
-38,526
-87% -$985K
ACHC icon
157
Acadia Healthcare
ACHC
$3.17B
– –
-81,630
Closed -$1.16M
ACLX
158
DELISTED
Arcellx
ACLX
– –
-75,002
Closed -$4.89M
AFRM icon
159
Affirm
AFRM
$25.5B
– –
-13,086
Closed -$974K
AGIO icon
160
Agios Pharmaceuticals
AGIO
$2.36B
– –
-147,662
Closed -$4.02M
ALC icon
161
Alcon
ALC
$34.3B
– –
-10,440
Closed -$661K
ALV icon
162
Autoliv
ALV
$9B
– –
-5,243
Closed -$622K
APLS
163
DELISTED
Apellis Pharmaceuticals
APLS
– –
-150,776
Closed -$3.79M
APP icon
164
Applovin
APP
$143B
– –
-2,482
Closed -$1.67M
BVN icon
165
Compañía de Minas Buenaventura
BVN
$7.68B
– –
-29,649
Closed -$825K
CDTX
166
DELISTED
Cidara Therapeutics
CDTX
– –
-22,928
Closed -$5.06M
CMPX icon
167
Compass Therapeutics
CMPX
$369M
– –
-245,532
Closed -$1.32M
CNX icon
168
CNX Resources
CNX
$4.71B
– –
-17,624
Closed -$648K
DBVT
169
DBV Technologies
DBVT
$870M
– –
-15,877
Closed -$304K
FOUR icon
170
Shift4
FOUR
$3.99B
– –
-12,982
Closed -$817K
GTLB icon
171
GitLab
GTLB
$5.53B
– –
-19,305
Closed -$725K
OFIX icon
172
Orthofix Medical
OFIX
$468M
– –
-85,049
Closed -$1.29M
RBLX icon
173
Roblox
RBLX
$37B
– –
-8,431
Closed -$683K
RNAM
174
DELISTED
Avidity Biosciences
RNAM
– –
-40,020
Closed -$2.89M
SCHW
175
Charles Schwab
SCHW
$177B
– –
-10,601
Closed -$1.06M
4 5 6
7
8

Similar funds

RWM
Revisor Wealth Management Akron, Ohio $362M AUM 15.97% 1-Year Est. Return
SIAG
Safeguard Investment Advisory Group Corona, California $362M AUM 20.96% 1-Year Est. Return
WI
WBI Investments Red Bank, New Jersey $362M AUM 23.75% 1-Year Est. Return
MSL
MILLINGTON SECURITIES, LLC Red Bank, New Jersey $362M AUM
BHBT
Burke & Herbert Bank & Trust Alexandria, Virginia $362M AUM 20.5% 1-Year Est. Return
CAP
Cordoba Advisory Partners New York $362M AUM
WTFG
Wood Tarver Financial Group Boise, Idaho $362M AUM 14.75% 1-Year Est. Return
RC
Reik & Co New York $363M AUM 3.03% 1-Year Est. Return

HighVista Strategies's Q1 2026 Portfolio in Review

As of Q1 2026, HighVista Strategies held 180 positions worth $362M, down 6.7% from $388M the previous quarter. Its ten largest holdings account for 27% of the portfolio.

HighVista Strategies withdrew a net $33.3M in Q1 2026, closing 24 positions and reducing 71 holdings. Its most notable exit was Cidara Therapeutics, an estimated $5.06M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 67% of assets, down from 70% a quarter earlier, followed by Technology and Industrials.

Against the trend, HighVista Strategies opened a new position in Nurix Therapeutics worth $3.51M.

  • HighVista Strategies's largest Q1 2026 buy was Nurix Therapeutics: 226,546 shares worth $3.51M.
  • HighVista Strategies added most to Abivax in Q1 2026, an estimated $4.86M increase.
  • HighVista Strategies's biggest Q1 2026 reduction was Viridian Therapeutics, cutting an estimated $7.08M.
  • HighVista Strategies fully exited Cidara Therapeutics in Q1 2026, selling an estimated $5.06M.
  • HighVista Strategies's ten largest holdings make up 27% of its $362M portfolio in Q1 2026.
  • HighVista Strategies opened 35 new positions and closed 24 in Q1 2026.
  • HighVista Strategies's portfolio value fell 6.7% quarter-over-quarter to $362M.

Based on HighVista Strategies's 13F filing for Q1 2026, filed 15 May 2026.